Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

G-CSF Priming’s Impact on Bone Marrow Harvest

Biol Blood Marrow Transplant; ePub 2017 Oct 23; Furey, et al

Publish date:

At a certain threshold, increasing CD34+ cell dose did not impact bone marrow transplant outcomes in a study involving bone marrow harvests and pediatric recipient/donor duos. Using data from bone marrow harvests (n=92), investigators looked at how 1) granulocyte colony-stimulating factor (G-CSF) impacted cellular composition of harvested bone marrow and 2) CD34+ cell dose affected clinical outcomes in sibling recipient/donor duos (n=69). Among the results:

  • Average donor and recipient ages were ~10 and ~12 years, respectively.
  • G-CSF priming was not linked with higher yield of CD34+ cells/microliter.
  • The median CD34+ cell count/microliter obtained from donors <6 years of age was 700.
  • In those 6 to 12 and >12 years of age, these counts were 360 and 300, respectively.
  • Whereas the number of CD34+ cells infused did not affect traditional outcomes, it was significantly related to GVHD/relapse/rejection-free survival.

The authors concluded that a CD34+ cell count of approximately 3-5x106/kg was the threshold beyond which increasing CD34+ cell dose did not impact outcomes.

Citation:

Furey A, Rastogi S, Prince R, et al. Bone marrow harvest in pediatric sibling donors: Role of G-CSF priming and CD34+ cell dose. [Published online ahead of print October 23, 2017]. Biol Blood Marrow Transplant. doi:10.1016/j.bbmt.2017.10.031.

This Week's Must Reads